This reduction was not statistically significant (p=0.216; HR 0.92) compared to patients receiving placebo in addition to current standard of care. Results of the main secondary endpoint of
Pursuant to the agreement, both the companies will work together to develop a superior breast cancer prognostic test using Health Discovery Corporation’s (HDC’s) support vector machine technology in
These results pertaining to overall survival, a secondary endpoint, are an update to the previously reported results for progression-free survival (PFS), the study’s primary endpoint, which were announced
Dr Tamura has recently retired as representative director, executive vice president and chief science officer of Astellas Pharma. Dr Tamura has received a PhD degree from the University
The CE mark expands Hoana’s patient safety reach to include more than 30 countries in the EU. Hoana’s technology is said to transform any hospital bed into a
Under the agreement, JAC will offer a variety of products including specialized cabinets for controlled drugs, night use on wards, and in environments where access to medicines needs
According to the company, the 2D cardiac performance analysis is a speckle tracking based analysis tool which can analyze 2D data from various ultrasound machines. The user can
Intelence is said to be the first new non-nucleoside reverse transcriptase inhibitor to be introduced in approximately 10 years. Also known as TMC125, Intelence will be marketed in
The Kerol emulsion is supplied in a 10oz tube for application to larger skin surface areas. Kerol ZX is now supplied in a 12ml pre-filled applicator to deliver
The basic and enantiomer patents were challenged by generics manufacturer Ranbaxy. The court ruled that the basic patent, which expires in November 2011, would be infringed by Ranbaxy’s
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.